View in EDS

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.

Saved in:
Bibliographic Details
Title: Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.
Authors: Wu, Yi-Long1 syylwu@live.cn, Lee, Victor2,3 vhflee@hku.hk, Liam, Chong-Kin4 liamck@ummc.edu.my, Lu, Shun5 shunlu@sjtu.edu.cn, Park, Keunchil6 kpark@skku.edu, Srimuninnimit, Vichien7 vsiriraj@gmail.com, Wang, Jie8 zlhuxi@163.com, Zhou, Caicun9 caicunzhoudr@163.com, Appius, Anita10 anita.appius@roche.com, Button, Peter1,11 peter@ozbiostat.com, Hooper, Gregory12 greg.hooper@roche.com, Palma, John F.13 john.palma@roche.com, Schulze, Katja13 schulze.katja.ks2@gene.com, Scudder, Sidney13 sid.scudder@roche.com, Shames, David S.14 shames.david@gene.com, Yin, Anny-Yue1,15 yinyue@cstonepharma.com, Zhang, Guili13 guili.zhang@roche.com, Mok, Tony16 tony@clo.cuhk.edu.hk
Source: Lung Cancer (01695002). Dec2018, Vol. 126, p1-8. 8p.
Database: Academic Search Ultimate
Description
ISSN:01695002
DOI:10.1016/j.lungcan.2018.10.004